NEW YORK, NY--(Marketwire - September 24, 2007) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Oregon Health and Science University, Portland, Oregon.

Oregon's Health and Science University (OHSU) is the state's only health and research university. As part of its multifaceted public mission, OHSU strives for excellence in scholarship, research, clinical practice and community service. OHSU strives to provide high-quality health care emphasizing the development and dissemination of new knowledge and cutting-edge technology.

OHSU employs 11,500 people and is Portland's largest business with an annual budget of $1.18 billion. Approximately 52% of its annual budget contributes to patient care for 447 staffed beds at OHSU Hospital and Doernbecher Children's Hospital.

In keeping with OHSU's mission to develop and disseminate cutting-edge technology, Daxor's BVA-100 Blood Volume Analyzer will be utilized to measure intravascular blood volume on critically injured patients to diagnose the blood volume status post-injury and post-operatively. Current practices associated with treatment of these types of patients currently relies on surrogate markers such as the hematocrit, heart rate, blood pressure and highly invasive procedures which measure pressures and various hemodynamic variables but do not measure a patient's intravascular blood volume. OHSU's use of the BVA-100 will quantify the improvements to patient care and patient outcomes by utilizing a direct measured blood volume provided by the BVA-100 versus the use of surrogate markers and surrogate measurements.

Daxor's Blood Volume Analyzer BVA-100 is the only FDA-approved instrument for the direct measurement of a patient's intravascular blood volume. Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website

Contact Information: Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 Diane Meegan Investor Relations 212-330-8512